Theratechnologies Partners with Ionis for Innovative Therapies
Addition of investigational RNA-targeted medicines builds upon Theratechnologies’ foundational HIV portfolio as they pave the way for growth in Canada.
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading pharmaceutical company focused on innovative therapy commercialization, has proudly announced a new agreement with Ionis Pharmaceuticals, Inc. This exciting collaboration allows Theratechnologies to exclusively license two investigational RNA-targeted medications in Canada: olezarsen and donidalorsen.
The agreement aims to address significant unmet medical needs, with olezarsen being evaluated for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), while donidalorsen is being developed for the treatment of hereditary angioedema (HAE). Paul Lévesque, President and CEO of Theratechnologies, emphasizes the importance of this partnership for advancing healthcare innovations across Canada.
Key Highlights of the Agreement
Theratechnologies is eager to enhance their portfolio by bringing these two innovative treatments to the Canadian market. The exclusive rights granted under this licensing agreement signify a major step in their mission to improve the lives of patients facing serious health challenges.
Lévesque stated, "We are thrilled to be Ionis' partner, amplifying our foundational HIV portfolio and expanding our capabilities. This agreement stands as a testament to our expertise in advancing healthcare innovation in North America."
Brett Monia, CEO of Ionis, also shared his excitement, noting the synergy between their regional focus and the goal of delivering pioneering new medicines to patients with serious conditions.
Understanding Olezarsen and Its Potential Impact
Olezarsen is an innovative RNA-targeted therapy designed to significantly lower the production of apoC-III, a liver protein vital for managing triglyceride (TG) metabolism.
This medication seeks to address FCS, a rare condition marked by extremely high TG levels which can lead to debilitating symptoms and life-threatening pancreatitis. In some areas, such as Eastern Québec, FCS prevalence is notably higher, with estimates suggesting a ratio of 1:10,000. Additionally, sHTG represents a broader challenge, affecting a larger patient population, with approximately 3 million individuals in the U.S. expected to benefit from this treatment.
The FDA has accepted the New Drug Application (NDA) for olezarsen under Priority Review status, designating it as an Orphan Drug. A pivotal decision is anticipated around December 19, 2024. If successful, Theratechnologies aims to submit olezarsen for review in Canada in 2025, potentially marking the first approved FCS treatment in the country.
Donidalorsen: A Promising Alternative for HAE
Donidalorsen targets the prekallikrein protein, crucial in promoting inflammation during HAE attacks. This condition, though rare, poses significant risks with potential recurrence of severe and life-threatening swelling episodes.
Currently, the combined global prevalence of HAE is about one in every 50,000 people. The growing interest from both the FDA and European regulatory agencies underscores the urgency for effective treatments. Donidalorsen's NDA is under review, with a target PDUFA date set for August 21, 2025.
Financial Overview of the Licensing Agreement
The financial terms of the agreement between Theratechnologies and Ionis include a $10 million upfront payment, along with potential milestone payments totaling up to $12.75 million for achieving specific regulatory and commercial successes.
In terms of revenue, Ionis will receive tiered royalties on the net sales from both therapies, further underscoring the commercial potential of these innovative drugs. Theratechnologies will spearhead efforts to secure regulatory approval and maintain compliance in Canada.
This agreement marks an important commitment by Theratechnologies to provide access to vital new medicines, cementing its position as a front-runner in addressing chronic and debilitating health conditions.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is dedicated to developing and commercializing therapies that address serious medical needs. The company's ongoing mission is driven by its commitment to innovation and patient care.
To learn more about Theratechnologies, visit their official website and keep abreast of their partnerships and product development news.
Frequently Asked Questions
What is the significance of the licensing agreement between Theratechnologies and Ionis?
This agreement grants Theratechnologies exclusive rights to commercialize two promising RNA-targeted treatments in Canada, enhancing their product portfolio.
What diseases are targeted by olezarsen and donidalorsen?
Olezarsen aims to treat familial chylomicronemia syndrome and severe hypertriglyceridemia, while donidalorsen is focused on hereditary angioedema.
When does Theratechnologies plan to submit its applications to Health Canada?
The company is preparing to submit applications for olezarsen and donidalorsen in 2025, pending FDA approvals.
What are the financial terms of the agreement?
The agreement includes an upfront payment of $10 million, potential milestone payments, and tiered royalties for Ionis on net sales.
How is Theratechnologies enhancing its therapeutic portfolio?
By entering into this partnership, Theratechnologies is expanding beyond its foundational HIV therapies to include vital new RNA-targeted therapies.
